Jiamin Du
Zhejiang Province Key Laboratory Of Anti Cancer Drug Research
Hangzhou, China
Hangzhou, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 10 publications
Deubiquitinating enzyme JOSD2 modulates cGAS to facilitate immune evasion in colorectal cancer.
Journal: Oncoimmunology
Published: December 06, 2025
USP10-mediated deubiquitination and activation of KRAS mutants promotes colorectal cancer via a novel USP10/KRAS positive feedback circuit.
Journal: Acta pharmaceutica Sinica. B
Published: February 22, 2025
JOSD2 promotes breast cancer metastasis by deubiquitinating and stabilizing SMAD4.
Journal: Biochemical pharmacology
Published: September 30, 2024
Josephin domain containing 2 (JOSD2) promotes lung cancer by inhibiting LKB1 (Liver kinase B1) activity.
Journal: Signal transduction and targeted therapy
Published: January 05, 2023
Fingolimod exerts in vitro anticancer activity against hepatocellular carcinoma cell lines via YAP/TAZ suppression.
Journal: Acta pharmaceutica (Zagreb, Croatia)
Published: January 19, 2022
SDHA/B reduction promotes hepatocellular carcinoma by facilitating the deNEDDylation of cullin1 and stabilizing YAP/TAZ.
Journal: Hepatology (Baltimore, Md.)
Published: November 30, 2021
The calcimimetic agent cinacalcet inhibits hepatocellular carcinoma via YAP/TAZ suppression.
Journal: Die Pharmazie
Published: October 08, 2021
The role of cGAS-STING signalling in liver diseases.
Journal: JHEP reports : innovation in hepatology
Published: March 13, 2021
Deubiquitinase JOSD2 stabilizes YAP/TAZ to promote cholangiocarcinoma progression.
Journal: Acta pharmaceutica Sinica. B
Published: December 21, 2020
Targeting slug-mediated non-canonical activation of c-Met to overcome chemo-resistance in metastatic ovarian cancer cells.
Journal: Acta pharmaceutica Sinica. B
Published: January 03, 2019
Showing 1-10 of 10
Last Updated: 09/26/2026